000			01670cam a2200289 4500500
005			20250112035953.0
041			_afre
042			_adc
100	1	0	_aRahmé, Ramy _eauthor
700	1	0	_a Braun, Thorsten _eauthor
245	0	0	_aXPO1 inhibitors in the treatment of hematologic malignancies: From preclinical findings to clinical studies
260			_c2023.
500			_a15
520			_aExportin 1 (XPO1) is a nuclear receptor that is involved in the phenomenon of nuclear export. A high expression of XPO1 is associated with reduced survival in hematologic malignancies. The inhibition of XPO1 was shown to be effective in multiple preclinical models. Selinexor was the main inhibitor tested in clinical trials, both in lymphoid and myeloid hemopathies. Its efficacy is generally moderate with an average pathology-dependent tolerability profile. Selinexor currently has temporary authorization for use in France in the treatment of multiple myeloma after failure of four lines of treatment and in non-Hodgkin lymphomas after failure of two lines. A better selection of patients with higher susceptibility to XPO1 inhibition and the development of second-generation inhibitors with lower digestive toxicity may revive the clinical development of XPO1 inhibitors.
690			_amyeloma
690			_aleukemia
690			_aXPO1
690			_aselinexor
690			_alymphoma
690			_amyeloma
690			_aleukemia
690			_aXPO1
690			_aselinexor
690			_alymphoma
786	0		_nHématologie | 29 | 3 | 2023-05-02 | p. 157-170 | 1264-7527
856	4	1	_uhttps://shs.cairn.info/journal-hematologie-2023-3-page-157?lang=en
999			_c174686 _d174686